Sirnaomics Ltd delivered a QQ2 2025 result set that underscores the company’s status as an early-stage RNA therapeutics player: minimal near-term revenue, substantial investment in R&D and G&A, and meaningful cash burn. Revenue for the quarter was USD 81,000, with a gross profit of USD 81,000 and a gross margin of 100% as cost of revenue was not reported, consistent with a development-stage biotech model without commercial products in revenue. However, operating expenses dominated the P&L, totaling USD 5.598 million (R&D USD 3.045 million and G&A USD 2.553 million), producing an EBITDA of USD -4.692 million and a net loss of USD -3.698 million, or -45.65% net margin. Diluted EPS stood at -0.0394. The quarter contributes to a broader burn profile typical of pre-commercial biotechs, raising questions about runway, funding strategy, and potential dilution risk.